(Total Views: 636)
Posted On: 09/29/2022 3:03:20 AM
Post# of 155005
Whether they go forward with the BLA will be dependent on anticipated profit from the now lowered market share vs. cost to rework the BLA vs. opportunity costs of redoing the BLA in regards to other indications.
What wasn't mentioned but I'm sure is being taken into account is the 12 year exclusivity. If HIV is approved 2 years before other indications that knocks 2 years off the exclusivity for those other indications.
Of course we can slip in the backdoor with NASH/HIV patients. There is also the work of Dr. Sacha which could make leronlimab the preeminent drug in the HIV space with major market share.
What wasn't mentioned but I'm sure is being taken into account is the 12 year exclusivity. If HIV is approved 2 years before other indications that knocks 2 years off the exclusivity for those other indications.
Of course we can slip in the backdoor with NASH/HIV patients. There is also the work of Dr. Sacha which could make leronlimab the preeminent drug in the HIV space with major market share.
(14)
(0)
